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Scope: Inflammatory status can increase the risk of adverse cardiovascular events linked
to platelet activity and involvement of microparticles (MP) released from platelets (PMP),
leukocytes (LMP), and monocytes (MMP). These MP carry host cell-derived antigens that may
act as markers of metabolic health. Subjects newly diagnosed with type 2 diabetes are offered
appropriate standard dietary advice (SDA) but this may not be optimal as specific inclusion of
other nutrients, such as oats, may add benefit. The effectiveness of such interventions can be
tested by examination of MP activation markers.
Methods and results: Subjects (n = 22) with type 2 diabetes participated in a randomized
cross-over trial involving 8 wk interventions with either an oat-enriched diet (OAT) or following
reinforced SDA. Responses were also compared with preintervention habitual (HAB) intake.
OAT reduced the concentrations and proportions of fibrinogen- and tissue factor-related PMP
and MMP_11b. The main effect of SDA was to reduce fibrinogen-activated PMP. Regardless
of chronic intake, a healthy test meal led to postprandial declines in total PMP as well as tissue
factor-, fibrinogen-, and P-selectin-positive PMP.
Conclusion: OAT improved risk factors assessed by MP status, even in subjects with type 2
diabetes already well-controlled by diet and life-style alone.
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1 Introduction
Although circulating microparticles (MP; small vesicles,
ranging in size from 0.1 to 1.0 m in diameter [1–3]) can
be released from a range of cell types, including leukocytes,
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lymphocytes, erythrocytes, and endothelial cells, following
activation or apoptosis, the majority (approximately 70–90%)
are derived from platelets [4–6]. Following activation, through
membrane fusion and internalization theseMP transfer com-
ponents, including proteins, lipids, and receptors, to various
target cells with resultant contributions to inflammation, co-
agulation, and vascular dysfunction events [7]. Notably, MP
create a surface environment favorable for thrombin forma-
tion and synthesis of cytokines, with impacts on platelet, en-
dothelial, and monocyte activation that may contribute to the
development of cardiovascular disease (CVD) [8]. For exam-
ple, the increased plasma concentrations of cell-derived MP
observed in patients with CVDs, or other ailments associated
with vascular impairment [1,4,9–15] including diabetesmelli-
tus [11,14,16], have been proposed as biomarkers of vascular
health, or even prognostic markers for atherosclerotic dis-
ease [17–19]. Indeed, our previous study demonstrated that
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platelet-derived MP (PMP) markers, linked to pathways re-
lated to vascular inflammation, differed between healthy sub-
jects and those with type 2 diabetes, independent of obesity
status [20]. Such data suggest that both the concentrations
and activation status of PMP may represent markers of sub-
tle changes in subclinical inflammation and identify mecha-
nisms that link inflammation to disease.
Dietary and life-style interventions are the first line man-
agement for a number of important chronic diseases, in-
cluding newly diagnosed type 2 diabetes [21]. A large body
of data suggest that low glycemic index (GI) diets can aid
glycemic control [22–28]. Furthermore, postprandial hyper-
glycemia may be particularly harmful in terms of cardiovas-
cular risk [29,30], related to acute increases in plasma concen-
trations of markers of systemic inflammation and oxidative
stress [31–34]. Platelet activation status can alter in response
to consumption of single meals, although the responses have
not been consistent [35–38]. These contradictory outcomes
may depend on both subject status, e.g. with or without type
2 diabetes, and the type ofmeal offered. Furthermore, data on
changes in MP from various origins in response to chronic
dietary consumption are limited.
The current report examines the impact of chronic (8 wk)
consumption of either an oat-enriched diet (OAT) or one
based on the standard dietary advice (SDA) provided in the
UK to subjects with type 2 diabetes, controlled by diet and
lifestyle alone, on indices of MP. The OAT diet was investi-
gated because, first, oats are considered a lowGI food [39] and,
as such, might be expected to modulate postprandial hyper-
glycemia [40]. Second, oats can exert direct anti-inflammatory
and antioxidant properties [41, 42]. The hypothesis was that
OATs would improve fasting inflammation status, as as-
sessed by platelet markers, especially MP, compared with
either the habitual (HAB) diet or SDA.
2 Materials and methods
2.1 Subjects
Measurementsweremade in a subset (n= 22) of patientswith
type 2 diabetes, controlled by diet and life-style alone, from
a larger study [43]. Both male and postmenopausal females
(age 40–75 years) with type 2 diabetes were recruited from two
Scottish Health Boards, Grampian (centered at Aberdeen)
and Highland and Islands (centered at Inverness). Inclusion
criteria included either newly diagnosed type 2 diabetes or
with the disease controlled by diet and life-style alone. Exclu-
sion criteria included significant liver, renal, cardiovascular
or psychiatric illness, plus medications that might invalidate
the study results (including oral hypoglycemic drugs, cor-
ticosteroids, hormone replacement therapy anticoagulants,
aspirin, and statins). Recruitment protocols included news-
paper and poster advertisement plus approaches based on
searches of patient databases followed by approval to con-
tact from the appropriate General Practitioner. All volunteers
provided signed consent. The study was approved by
the North of Scotland Research Ethics Committee
(07/S0802/163) and registered with the ISRCTNRegister (IS-
RCTN12655129).
2.2 Experimental protocol
The full study details and subject characteristics have been
provided elsewhere [43]. Briefly, the volunteers had all been
diagnosed previously with type 2 diabetes by Aberdeen or In-
verness Diabetes Clinics, part of the Scottish National Health
Service, based on a combination of fasting (>7 mmol/L) or
random glucose (>11 mmol/L) on at least two occasions or
response to an oral glucose tolerance test (>11 mmol/L, 2 h
after ingestion of 75 g glucose) but all had <64 mmol/mol
glycosylated hemoglobin (HbA1c). All volunteers had been
offered advice on diet and lifestyle at diagnosis and had used
this to control their diabetes without need for specific medi-
cation. At recruitment, fasting glucose and insulin were 7.7
mmol/L and 11.0 mU/L, with HOMA-IR 3.9 [43]. At entry to
the study, subjects were following their habitual diet (HAB)
and were randomly allocated to a cross-over design with each
arm of 8 wk that involved either their normal diet but with
part of their carbohydrate intake substituted with a range
of oat products (OAT) that were provided or by following a
reinforcement of the SDA routinely offered at diagnosis and
based predominantly on ‘‘Eating well with diabetes’’ provided
by Diabetes UK. While on SDA, the subjects were asked to
minimize their intake of oats (this decreased from 32 g/d
HAB to 5 g/d SDA). For the OAT arm, subjects were pro-
vided with written guidelines on how to include a minimum
of 70–100 g oat products into their daily diet (mean intake
was 131 g/d). A range of suitable oat products available com-
mercially were provided gratis to the subjects. Measurements
were made on entry to the study (HAB) and at the end of the
two intervention periods (OAT and SDA) and involved anal-
ysis of overnight fasted blood samples and the subsequent
response to a standardized test meal [43]. This test meal fol-
lowed the recommendation of Diabetes UK for healthy eating
and allowed investigation of the postprandial effects on MP
concentrations and activation in subjects with type 2 diabetes.
Overnight fasted blood samples were taken and then sub-
jects were offered the healthy test meal, consumed within 15
min. The test meal comprised 3.3 MJ metabolizable energy
as 28 g protein, 104.5 g carbohydrate (of which sugar 30.6
g), 29.1 g fat (of which saturates 8.6 g), and fiber 11.2 g [43].
The GI was estimated at 57.1, with available carbohydrate of
92.7 g and with a glycemic load of 52.9 g. Blood samples were
withdrawn at 15 min intervals for 3 h following the meal [43],
but only those taken at 0, 90, and 180 min were analyzed for
platelet and MP characteristics. Other than dietary interven-
tion, diabetes care and management of the subjects was not
altered during the study.
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2.3 Platelet activation status
Blood (10 mL) from the overnight fasted state was collected
into sodiumcitrate tubes (S-Monovette, Sarstedt, Numbrecht,
Germany) and the whole blood count for leukocyte, lympho-
cyte, and platelet quantities (counts/ L) was analyzed with a
Sysmex KX21 (Sysmex Ltd, UK). The proportions of platelets
with activation markers for fibrinogen, tissue factor (TF), and
CD62P were determined as described elsewhere [44].
2.4 Microparticle measurements
2.4.1 Isolation of MPs and flow cytometry detection
Blood (10 mL) was collected into sodium citrate S-monovette
tubes and centrifuged at 2000× g for 20min to isolate platelet-
poor plasma that was then stored at −80C prior to isolation
and measurement of MP as described previously [20]. To
20 L of the MP suspension was added 80 L HEPES buffer
and themixture was incubated in the dark for 20min at room
temperature together with appropriate monoclonal antibod-
ies conjugated with separate fluorescentmarkers; fluorescein
isothiocyanate (FITC), phycoerythrine (PE), peridinin chloro-
phyll protein (PerCP) or allophycocyanin (APC), and analyzed
as described previously (see Table 1) [20].
2.5 Clinical and glycemic measurements
Total cholesterol, LDL, oxidized-LDL, high-density lipopro-
tein (HDL), triglycerides C-reactive protein (CRP), and
interleukin-18 were measured as described for the larger
study [43] as were oxygen radical antioxidant capacity (ORAC)
and urinary isoprostanes.
2.6 Statistical methods
Unless otherwise stated, data were obtained from 22 volun-
teers, who received three chronic dietary interventions with
a test meal measured at 3 time points at the end of each in-
tervention. Data were analyzed by restricted maximum likeli-
hood (REML) using Genstat 13th Edition Release 13.2 (VSN
International, Hemel Hempstead, Herts, UK). Random ef-
fects consisted of volunteer, with week and time, plus their
interaction, nested within volunteer. Fixed effects were site,
gender, diet, time, and week with all interactions between
diet, time, and week considered. Site and gender interactions
were restricted to those with diet and week. Data are sum-
marized as means ± SEM, based on the between-volunteer
spread. To allow comparison of mean values the correspond-
ing standard error of difference (SED) is also presented,
obtained from the residual variance of the appropriate er-
ror stratum. Where significant responses (p < 0.05) were
observed for main effects or interactions then posthoc t-tests
were applied to determine which mean values differed.
Based on visual inspection of the residual plots, data for
MP numbers and activation status were log-transformed in
order to stabilize the variance. For these data the means are
presented after back-transformation based on first order Tay-
lor approximation. The corresponding SEM and SED were
obtained from back transformation of the residual variance
from the appropriate error stratum of the REML output. For
outcomes related to PMP no significant diet × time interac-
tions were observed. Therefore, for these outcomes only the
main effects of either diet or time are presented from the full
analysis (but which still included diet× time interactions). In
contrast, there were significant diet × time interactions for
certain leukocyte-derived microparticles (LMPs) and MMP
outcomes. These interactions are detailed in the text, while
the main effects for either diet or time are included in the
various tables.
For overnight fasted data, relationships betweenMPmark-
ers (log transformed) and other inflammatory markers (un-
transformed) were investigated with random effects regres-
sion using REML with subject as a random effect. Biological
meaning was only ascribed to regression relationships at p<
0.01.
3 Results
3.1 Concentrations of MP
The concentrations of the various MP varied considerably
between volunteers, as shown in Figs. 1A and 1B which are
based on themeans of rawdata for the nine observations from
each subject, i.e. the three dietary interventions (HAB, OAT,
and SDA) and the three sample times accompanying the test
meal (0, 90, 180 min) are combined. The between-volunteer
variability necessitated log transformation of the data prior to
statistical analysis.
3.2 Effects of chronic dietary intervention
3.2.1 Platelet count and platelet activation status
Only at the Aberdeen site was it possible to measure platelet
count, volume, and activation status (n = 14). Neither base-
line platelet counts nor platelet volume were impacted by
chronic dietary status (Table 2). In terms of platelet activa-
tion status, the proportion of baseline samples that contained
tissue factor-activated platelets was lower (−23%, p = 0.004)
after intervention with OAT than for either HAB or SDA.
3.2.2 MP count and MP activation status
Both absolute counts (gate counts/L) and proportion of
MP were decreased (p < 0.05) for CD11b-positive MMP,
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Table 1. Antibodies used and the microparticles targeted
Antibody Targeted microparticle Name of antigen
CD61 + a) PMP Integrin beta-3
CD61+/fibrinogen+ a),c) Fibrinogen-positive PMP Integrin beta-3/Fibrinogen
CD61+/CD62P+ a),b) P-selectin-positive PMP Integrin beta-3/P-selectin
CD61+/CD142+ c),d) TF-positive PMP Integrin beta-3/Tissue Factor
CD45+ e) LMP Leukocyte common antigen
CD45+/CD14+ e),f) MMP Leukocyte common antigen/Monocyte differentiation antigen
CD14
CD45+/CD11b+ e),g) CD11b-positive-LMP Leukocyte common antigen/Integrin alpha M
CD45+/CD14+/CD11b+ e),f),g) CD11b-positive-MMP Leukocyte common antigen/Monocyte differentiation antigen
CD14/ Integrin alpha M
a) anti-CD61-PerCP (BD Bioscience, San Jose, CA, USA); b) anti-CD62P-APC (BD Pharmingen, BD Bioscience, San Diego, CA, USA); c)
anti-fibrinogen-FITC (DakoCytomation, Glostrup, Denmark); d) anti-tissue factor-FITC (American Diagnostica, Stamford, CT, USA); e) anti-
CD45-PE (BD Pharmingen, BD Bioscience); f) anti-CD14-APC (BD Bioscience); g) anti-CD11b-FITC (Beckman Coulter, Paris, France). FITC-,
PE-, PerCP- and APC-conjugated isotype controls (IgG1, BD Bioscience) were used to define the background noise of the labeling.
fibrinogen-positive PMP, and tissue factor-positive PMP after
OAT intervention compared with HAB (Table 3). The con-
centrations and proportion of fibrinogen-positive PMP also
decreased (p < 0.01) after the SDA intervention compared
with HAB. There were no differences, however, for MP con-
centrations and activation status between the OAT and SDA
interventions. The chronic diet intervention had no effect on
LMP counts (data not shown).
3.3 Postprandial effects
Counts of platelets, leukocytes, and lymphocytes within blood
all decreased (p < 0.01; Table 4) 90 min after meal ingestion
but either returned to premeal values by 180 min (platelets
and lymphocytes) or increased to above baseline (leukocytes;
p <0.01), In all cases the postprandial decreases at 90 min
exceeded any response due to hemodilution (based on−1.8%
changes in red blood cell and hemoglobin concentrations,
data not shown). The mean platelet volume was increased
slightly at 90 min (+2%, p = 0.003) and remained elevated at
180 min (p = 0.001; Table 4).
Compared with premeal values, postprandial declines
(p < 0.01) over 3 h were observed for concentrations of total
PMP and LMP, tissue factor-positive PMP and P-selectin-
positive PMP (Table 5). For the latter three, the decline was
fully established by 90 min. There was also a decrease (p <
0.05) in fibrinogen-positive PMP between 90 and 180 min.
In contrast, the proportions of both CD11b-positive LMP and
fibrinogen-positive PMP were increased (p < 0.01) at both
Figure 1. Plasma quantities (counts/L) of microparticle (MP) for individual subjects. Leukocyte-derived microparticles (LMP), monocyte-
derived microparticles (MMP), CD11b-positive leukocyte-derived microparticles (LMP_11b), CD11b-positive monocyte-derived microparti-
cles (MMP_11b), platelet-derived microparticles (PMP), fibrinogen-positive platelet-derived microparticles (PMP_fib), tissue factor-positive
platelet-derived microparticles (PMP_TF) and P-selectin-positive platelet-derived microparticles (PMP_psel). Data are based on raw obser-
vations, combined for the 9 samples taken for each subject (3 diets each with 3 time points). In boxplot format the shaded box encloses
the 25–75 percentile of the data, with the median indicated by a bar. Whiskers extend to 1.5 times of the box height or the most extreme
data point, whichever is smaller. The asterisks indicate those volunteers who fall outside these limits.
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Table 2. Overnight fasted plasma platelet count (counts/L), mean platelet volume (MPV; fL) and the percentage of platelets that express
P-selectin (%CD62P), fibrinogen (%fib), and tissue factor (%TF) following 8 wk of each dietary intervention (n = 14)
Diet Platelet 103/L MPVfL %CD62P %fib %TF
HAB 203 ± 13 8.5 ± 0.15 12.5 ± 2.6 18.1 ± 5.9 54 ± 6a
OAT 196 ± 10 8.6 ± 0.14 9.3 ± 1.6 17.6 ± 4.8 41 ± 5b
SDA 211 ± 10 8.4 ± 0.13 13.6 ± 3.1 14.4 ± 6.5 52 ± 5a
SED 13.7 0.23 2.7 7.5 4.3
p NS NS NS NS 0.004
Data are shown as means ± SEM (based on between-volunteer spread). SED, standard error of difference within volunteer, values within a
column with unlike superscripts differ by p < 0.05, NS not significant (p > 0.05). HAB, preintervention habitual diet; OAT, oat intervention;
SDA, standard dietary advice.
Table 3. Plasma activated microparticle amounts (gate counts/L) or as percentage of appropriate MP population following each dietary
intervention (n = 22)
Diet MMP_11b counts/L PMP_fib counts/L PMP_TF counts/L MMP_11b% PMP_fib% PMP_TF%
HAB 17.7 ± 4.1 1095.8 ± 150.3 176.5 ± 37.2 58.0 ± 2.4 58.9 ± 4.4 17.1 ± 3.3
OAT 6.4 ± 1.4 480.9 ± 54.8 101.9 ± 16.8 43.0 ± 2.2 33.1 ± 3.1 7.5 ± 0.9
SDA 8.8 ± 1.8 585.4 ± 60.8 126.2 ± 21.6 44.8 ± 2.4 39.4 ± 3.6 8.5 ± 0.9
SED 5.14 185.01 18.95 4.21 5.31 4.45
p 0.043 <0.001 0.007 0.001 <0.001 0.036
HAB versus OAT 0.015 0.002 0.013 < 0.001 <0.001 0.040
HAB versus SDA NS 0.013 NS 0.004 <0.001 NS
OAT versus SDA NS NS NS NS NS NS
Mean ± SEM (based on between-volunteer spread for the mean value of 3 time points on each test meal day). For absolute concentrations
the calculations (mean, SEM) and statistical analyses (SED, p-values) are based on the log-transformed data for monocyte (MMP) and
platelet (PMP) microparticles activated for fibrinogen (fib) or tissue factor (TF). The results presented are obtained from back transformation
of the means and appropriate residual variances. The percentage values and corresponding analyses are based on untransformed data.
p values within columns compared for overall diet effects and between each pair of chronic diets, NS not significant (p > 0.05). HAB,
pre-intervention habitual diet; OAT: oat intervention; SDA: standard dietary advice.
Table 4. Mean platelet volume (MPV; fL) and blood numbers (gate counts/L) of platelets, leukocytes, and lymphocytes during the post-
prandial period after the test meal (n = 14)
Time (min) Platelet 103/L MPVfL Leukocytes 103/L Lymphocyte 103/L
0 206.9 ± 7.2 8.4 ± 0.1 5.8 ± 0.2 1.9 ± 0.1
90 197.0 ± 7.8 8.6 ± 0.1 5.5 ± 0.2 1.7 ± 0.1
180 203.0 ± 7.7 8.6 ± 0.1 6.2 ± 0.2 1.9 ± 0.1
SED 2.09 0.058 0.108 0.063
p <0.001 <0.001 <0.001 <0.001
0 versus 90 <0.001 0.003 0.012 <0.001
0 versus 180 NS 0.001 0.005 NS
90 versus 180 0.008 NS <0.001 <0.001
Data are shown as means ± SEM (based on observed between-volunteer spread for each of the three sampling times (0, 90, 180 min)
following the test meal combined across all 3 dietary interventions (HAB, OAT and STD). p values within columns compared for overall
effect of time and between each time pair, NS not significant (p > 0.05).
90 and 180 min after the test meal. Diet × time interac-
tions were observed for concentrations of LMP (p < 0.001),
CD11b-positive-leukocyte-derived microparticles (LMP_11b)
(p = 0.009) and MMP (p = 0.040). These responses were
driven mainly by a continued decline in concentration over
the 180min of the testmeal forOATwhereas for theHABdiet
an initial decline at 90 min was then followed by an increase
at 180 min that exceeded the initial (time 0) value (Fig. 2).
3.4 MP regressed against other markers
In agreement with data from the main study [43], there were
no diet-related effects on glycemic control nor the glycemic
or insulinemic responses to the test-meal for the current
subpopulation (data not shown). In addition, neither oxida-
tive stress or inflammation were altered between OAT and
SDA (data not shown), again in agreement with the larger
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Table 5. Plasma microparticle concentrations (gate counts/L) or as percentage of appropriate MP population during the postprandial
period after the test meal (n = 22)
Time (min) LMP PMP PMP_fib PMP_TF PMP_psel LMP_11b% PMP_fib%
counts/L counts/L counts/L counts/L counts/L
0 157.6 ± 15.3 3145 ± 414 686.1 ± 87.4 161.2 ± 33.2 17.9 ± 3.5 41.6 ± 2.5 32.3 ± 3.5
90 122.2 ± 15.0 2160 ± 282 731.8 ± 95.2 122.8 ± 21.4 6.4 ± 1.4 47.7 ± 2.5 48.1 ± 4.2
180 124.1 ± 15.6 1515 ± 157 588.7 ± 72.4 112.5 ± 19.3 4.7 ± 0.8 46.7 ± 2.7 49.2 ± 3.7
SED 12.96 250.77 191.75 7.70 1.85 1.58 2.32
p 0.005 <0.001 0.032 <0.001 <0.001 0.005 <0.001
0 versus 90 0.003 0.007 NS 0.003 <0.001 <0.001 <0.001
0 versus 180 0.005 <0.001 NS <0.001 <0.001 0.003 <0.001
90 versus 180 NS 0.011 0.037 NS NS NS NS
Mean± SEM (based on between-volunteer spread observed in each of the three sampling times (0, 90, 180 min) following the test meal and
combined across all diets). For absolute concentrations the calculations (mean, SEM) and statistical analyses (SED, p-values) are based on
the log-transformed data. The results presented are obtained from back transformation of the means and appropriate residual variances.
Data for the percentages of LMP and PMP are based on untransformed values. NS, not significant (p > 0.05).
population [43]. Regression analysis (Table 6) showed that
concentrations of total PMP were negatively associated with
oxidized LDL (p = 0.041). Concentrations of P-selectin-
positive PMP were negatively associated with oxygen radical
antioxidant capacity (p = 0.004). LMP and CD11b-positive
LMP concentrations were positively associated with amounts
of oxidized LDL (p < 0.001) and total cholesterol (p = 0.024),
but negatively associated with urinary F2-isoprostanes (p =
0.039). MMP and CD11b-positive MMP concentrations were
positively associated with amounts of oxidized LDL (p <
0.001). Those relationships with p < 0.01 for activated MP
are also presented in graphical form (Fig. 3). No significant
relationships were observed between the various MP and ei-
ther C-reactive protein or interleukin-18.
4 Discussion
Associated with type 2 diabetes are a number of comor-
bidities, including several that impact on cardiovascular
events. For some patients changes in diet and lifestyle can
aid control of glycemia without the need for pharmaceutical
medications. In terms of diet, recommendations include re-
duced intake of fat and simple sugars and increased intake of
complex carbohydrates. Certain of the recommended foods
may have additional benefits as they contain compounds that
may mitigate some of the comorbidities. As oats are reported
to exert anti-inflammatory and antioxidant properties [41,42]
the impact of high intakes has been examined in the current
study based on changes in specific MP populations that have
been associated with atherosclerotic and cardiovascular risk.
There is no standard method for the MP detection and many
techniques have been used, including flow cytometry (FCM),
nanosight (nanoparticle tracking analysis), ELISA, and
electron microscopy [45–49]. These analytical methods give
different values for MP concentrations, a problem exacer-
bated by between-laboratory differences in procedures such
as MP storage and isolation, plus antibody specificity. The
current study used carefully standardized procedures [20]
for plasma collection, MP storage, and isolation plus use of
Figure 2. Plasma microparticle concentrations during the postprandial period after the test meal (n = 22). Data based on log-transformed
data with mean values obtained by back transformation for each of the three sampling times (0, 90, 180 min) following the test meal and
combined across all diets. Between diet comparisons at the same time point that are significantly different (p < 0.05) are shown by unlike
superscripts.
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Table 6. Linear regression outcomes between MP (log transformed) and other inflammatory markers (untransformed)
Cholesterol OxLDL ORAC Isoprostanes
LMP p 0.024 <0.001 NS 0.039
slope 0.139 0.016 −0.0003
LMP_11b p 0.049 <0.001 NS NS
slope 0.131 0.016
MMP p NS <0.001 NS NS
slope 0.021
MMP_11b p NS <0.001 NS NS
slope 0.026
PMP p NS 0.041 NS NS
slope −0.008
PMP_fib p NS NS NS NS
slope
PMP_TF p NS NS NS NS
slope
PMP_pesl p NS NS 0.004 NS
slope −0.031
Random effects linear regressionwithMPmarkers (counts/L, values log-transformed) as dependent variables against various independent
variables (untransformed), cholesterol (mmol/L), oxygen radical antioxidant capacity (ORAC; M Trolox equivalent), oxidized LDL (OxLDL;
U/L) and urinary isoprostanes (pg/mL). These were analyzed with Restricted Maximum Likelihood (REML) with subject set as a random
factor. There were no significant relationships observed for interleukin-18.
specific antibodies coupled with flow cytometry detection.
This and the cross-over within-subject design meant that
treatment effects could be detected with confidence.
4.1 Chronic diet intervention
Although many studies document increased concentrations
of circulating MP in various autoimmune, inflammatory
and CVD states, few have attempted to directly manipulate
these, or the proportions of associated functional surface
molecules, and certainly not by use of dietary interventions.
For the current study theMPmarkers selected included those
recently reported to differ between subjects with or without
type 2 diabetes [20] and that may reflect inflammatory status
and level of vascular dysfunction. Compared with HAB, the
OAT diet lowered both the plasma concentration and pro-
portion of CD11b-positive-monocyte-derived microparticles
(MMP_11b) (Table 3). The antibody used targets integrin al-
phaM (Mac-1), a protein subunit within the integrin alpha-M
beta-2 molecule expressed on the surface of many leukocytes.
Thismediates inflammation by regulating both leukocytemi-
gration and adhesion to the vascular wall [50]. LMP and other
MMP are involved in the preclinical stage of atherosclerotic
disease, with a link between LMP and the burden of subclini-
cal atherosclerosis within the arterial tree [51,52]. The current
data indicate that chronic ingestion of an OAT diet may
improve the status of early stage vascular inflammation,
Figure 3. Relationships between clinical parameters in subjects with type 2 diabetes and log-transformed concentrations of activated
microparticles: CD11b-positive leukocyte-derived microparticles (LMP_11b), CD11b-positive monocyte-derived microparticles (MMP_11b)
and p-selectin positive platelet-derived microparticles (PMP_psel). Points shown are the overnight fasted values for 22 volunteers for each
of the 3 diets (HAB, OAT, SDA). Data were analyzed by random effects regression using REML and with subject set as random factor to
allow for within-volunteer effects to be examined.
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possibly by downregulation of the recruitment of leukocytes
and LMP for endothelial cells, although this needs to be
tested. On their HAB diet the subjects consumed, on
average, 30 g oats daily but did gain an improvement, based
on MP parameters, when this was increased by 100 g/d.
Importantly, SDA conferred similar advantages to OAT
intervention. At diagnosis of type 2 diabetes, the subjects
had been provided with information on the diet inclusions
and exclusions recommended by Diabetes UK and they
achieved reasonable control of their condition by diet and
life-style alone. Nonetheless, reinforcement of the SDA as
part of inclusion within the current study did reduce the
activated MMP status (MMP_11b; Table 3) and suggests
that the subjects may have ‘‘drifted’’ from following the
ideal advice within their habitual intake. Therefore, although
these subjects were able to exert adequate glycemic control
without the need for medication there was still scope for
further improvement. This emphasizes the need for regular
reeducation in terms of diet (and other aspects of lifestyle)
as part of the monitoring of the disease. Emphasis on higher
inclusion of oats in the diet may also provide a simple
and readily-identifiable means for patients who have been
diagnosed with type 2 diabetes, or are at risk of such a
diagnosis, to improve some of the associated comorbidities.
Positive effects on health also may accrue from the lower
plasma concentrations and proportions of fibrinogen-positive
PMP (PMP_fib) after OAT and SDA intervention compared
with HAB. Fibrinogen is a soluble plasma glycoprotein,
capable of binding to the receptor integrin IIb3 on the
surface of activated platelets and PMP. This firms the ad-
hesion between platelets and the endothelium and provides
the initial base for leukocyte recruitment and subsequent
inflammation [53]. The reductions observed in response to
OAT and SDA, therefore, maymodulate the platelet adhesion
to the endothelium that occurs during the early stages of
inflammation and development of atherosclerosis. In future
studies, this hypothesis should be tested by measurement of
endothelial activation status.
In the current study, both the concentration and propor-
tion of TF-positive PMP were also reduced after OAT in-
tervention compared with HAB (Table 3). Tissue factor is
a main activator of blood coagulation in the extrinsic path-
way and plays an important role in the formation of throm-
bin [54–56]. Furthermore, TF may be involved in processes
other than coagulation, including transcellular signaling or
angiogenesis [57]. TheMP can transport TF via the negatively
charged phospholipids on the surface, with tissue factor-
positive-platelet-derived microparticles (PMP_TF) strongly
associated with hypercoagulation in the presence of vascu-
lar problems or inflammation, such as occurs in diabetes or
cancer [50,57,58]. Therefore, reductions in the concentration
of PMP_TF and the proportion of platelets with TF-activation
may indicate that chronic high oat consumption provides an
anti-inflammatory function.
Overall, the current data suggest that the potential health
benefits with the OAT diet might involve reduced release
of MP with inflammatory properties. Oats contain specific
polyphenols, the avenanthramides, known to possess positive
health benefits [59] through antioxidant, antigenotoxic, an-
tiatherogenic, and anti-inflammatory properties [42, 60–63].
The presence of avenanthramides may explain why the OAT
diet was superior to SDA in terms of beneficial effects on
numbers and activation status ofMP. Nonetheless, both OAT
and SDA caused improvement compared with the habitual
intake of these subjects with type 2 diabetes controlled by diet
and life style alone. Indeed, the reductions observed for both
MMP_11b, and PMP_fib returned subjects to values reported
for those without type 2 diabetes [20]. Therefore, either OAT
or a reinforced SDA strategy should be encouraged because
these may help control progression of the disease and reduce
the risk of adverse comorbidities.
4.2 Postprandial responses
Previous studies have reported postprandial effects onplatelet
activation. For example, in healthy subjects, either high car-
bohydrate plus low fat intake or insulin infusion decreased
both platelet activation and aggregation [35, 36]. In contrast,
others have reported that meal ingestion or postprandial hy-
perglycemia is associated with enhanced platelet activation
in patients with type 2 diabetes mellitus [37, 38]. In response
to the ‘‘healthy’’ test meal provided in the current study, the
decline in platelet numbers at 90 min was associated with
preferential loss of the smaller platelets, based on the ob-
served changes in mean volume (Table 4). Interestingly, the
recovery in platelet numbers 3 h after the meal appeared to
involve release of larger platelets into the blood, based on
the maintained mean size. Although this initial decrease was
followed by an increase in platelet numbers, there was a con-
tinued reduction in both total and activated forms of PMP,
including those with response elements to TF, p-selectin, and
fibrinogen (Table 5). The lower concentrations of the latter,
alone or in combination with the other activated forms,might
be beneficial for reducing platelet coagulation, platelet adhe-
sion to the endothelium [53], and the early risk of plaque
formation and thus emphasize the benefits of a ‘‘healthy’’
meal.
Leukocytes responded to the healthy test meal with a
decline after 90 min, similar to platelets, but then recovered
to values greater than preingestion by 3 h. The LMP response
showed similarity with PMP in that total numbers declined
in the postprandial period but the concentrations in activated
form were unchanged and so increased as proportion of total
LMP (Table 5). From other studies, fat loading is known to in-
crease leukocyte number (including monocytes, neutrophils,
and lymphocytes) and activation status (based on CD62L and
CD66B) for up to 8 h [64–67]. This was considered a reflection
of acute postprandial activation of inflammation but with
the mechanisms involved unclear [68]. In contrast, the meal
offered to the current volunteers was designed deliberately
to meet Diabetes UK guidelines and, as such, contained low
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amounts of fat. Whether the fat contents of the test meals in-
gested, or other factors, account for the difference in response
between the current study and the earlier reports [64–67] is
unknown, although not only the amount but also the form
of dietary fat can have an impact on postprandial endothelial
cell function and decrease the concentrations of vascular
adhesion molecules [69].Whatever the mechanism, although
the current data suggest that a healthy (low fat) meal reduces
LMP numbers this does not extend to the activated forms
and so it is unclear whether this will confer a direct health
benefit. Nonetheless, as high fat meals produce harmful
responses [64–67] the lack of response to the healthier type
of meal is obviously to be preferred, especially for subjects
who might be at risk of cardiovascular events.
4.3 Relationships between MP and biomarkers of
disease
Although both OAT and SDA interventions failed to alter
glycemia, inflammation, antioxidant capacity or oxidative
stress [43], there were significant associations between cer-
tain of these indices and levels of MP, suggesting that the
latter may provide sensitive markers to reflect subtle changes
in additional health risks during the early stages of type 2
diabetes.
In this study, LMP markers and MMP markers were
positively associated with oxidized LDL while PMP markers
showed a negative association (Table 6 and Fig. 3). Oxidized
LDL can affect monocytes, platelets, and endothelial cells,
and those interactions are important in the development of
vascular complications in thrombotic diseases. Increased con-
centrations of MP, especially LMP, have been associated with
greater oxidized LDL in various patient groups [70, 71], pos-
sibly due to the capacity for carriage of oxidized LDL by MP.
The current results may indicate that LMP, but not PMP, can
act as a carrier of oxidized LDL.
This study confirms and extends other observations that
demonstrate the sensitivity of platelet number, activity, and
associated circulating MP activation to various dietary inter-
ventions. A healthy chronic diet, but particularly one rich
in oats, appears to have positive effects in terms of lesser
numbers of circulating MP that contain features linked to in-
flammatory or antioxidant processes. Even the ingestion of a
single healthymeal can have positive effects, in contrast to the
negative responses observed by other studies where high fat
meals were provided. The long-term impact of such healthy
eating on other metabolic parameters, especially those linked
to markers of inflammation and CVD risk, needs to be eval-
uated and, coupled with information obtained from platelet
and MP analysis, used to help advise patients with type 2 dia-
betes of the best dietarymeans to help control their condition.
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